OBJECTIVE: To compare the safety and retention rate of TNF antagonists used in approved indications (AIs) and non-AIs. METHODS: Analysis of the Spanish registry BIOBADASER 2.0 (February 2000 to October 2009). Patients were classified into AIs and off-label uses (OUs), according to the European Medicines Agency approval. Retention rates, incidence rates (IRs) and IR ratios (IRRs) of adverse events (AEs) with 95% CI were compared between uses, by log-rank test, cause-specific Cox regression models and generalized linear models with Poisson's distribution. RESULTS: First treatment with TNF antagonist was available in 5150 patients, of whom 4594 (89%) were AIs (2854 RA, 882 AS and 858 PsA) and 556 (11%) were OUs [437 chronic arthropathies in the spectrum of SpAs (CA) and 119 chronic immune-mediated diseases (CIDs)]. The IR of AE was largest in CID (649 events per 1000 patient-years) and lowest in PsA (250 events per 1000 patient-years). The occurrence of AEs was significantly associated with OU [IRR of CA vs RA 1.33 (95% CI 1.19, 1.49); IRR of CID vs RA 1.94 (95% CI 1.62, 2.31). The largest hazard ratio for discontinuation was for CID vs RA (1.33; 95% CI 1.02, 1.71) and especially vs AS (2.18; 95% CI 1.63, 2.90). CONCLUSIONS: OUs of TNF antagonists need a very close ascertainment of risk/benefit. The safety and retention pattern for CID is similar to that for RA and the pattern for CA resembles that of AS. This study shows an additional value of a national registry.
OBJECTIVE: To compare the safety and retention rate of TNF antagonists used in approved indications (AIs) and non-AIs. METHODS: Analysis of the Spanish registry BIOBADASER 2.0 (February 2000 to October 2009). Patients were classified into AIs and off-label uses (OUs), according to the European Medicines Agency approval. Retention rates, incidence rates (IRs) and IR ratios (IRRs) of adverse events (AEs) with 95% CI were compared between uses, by log-rank test, cause-specific Cox regression models and generalized linear models with Poisson's distribution. RESULTS: First treatment with TNF antagonist was available in 5150 patients, of whom 4594 (89%) were AIs (2854 RA, 882 AS and 858 PsA) and 556 (11%) were OUs [437 chronic arthropathies in the spectrum of SpAs (CA) and 119 chronic immune-mediated diseases (CIDs)]. The IR of AE was largest in CID (649 events per 1000 patient-years) and lowest in PsA (250 events per 1000 patient-years). The occurrence of AEs was significantly associated with OU [IRR of CA vs RA 1.33 (95% CI 1.19, 1.49); IRR of CID vs RA 1.94 (95% CI 1.62, 2.31). The largest hazard ratio for discontinuation was for CID vs RA (1.33; 95% CI 1.02, 1.71) and especially vs AS (2.18; 95% CI 1.63, 2.90). CONCLUSIONS: OUs of TNF antagonists need a very close ascertainment of risk/benefit. The safety and retention pattern for CID is similar to that for RA and the pattern for CA resembles that of AS. This study shows an additional value of a national registry.
Authors: Yuan Luo; William K Thompson; Timothy M Herr; Zexian Zeng; Mark A Berendsen; Siddhartha R Jonnalagadda; Matthew B Carson; Justin Starren Journal: Drug Saf Date: 2017-11 Impact factor: 5.606
Authors: Louise K Mercer; Anne C Regierer; Xavier Mariette; William G Dixon; Eva Baecklund; Karin Hellgren; Lene Dreyer; Merete Lund Hetland; René Cordtz; Kimme Hyrich; Anja Strangfeld; Angela Zink; Helena Canhao; M Victoria Hernandez; Florence Tubach; Jacques-Eric Gottenberg; Jacques Morel; Jakub Zavada; Florenzo Iannone; Johan Askling; Joachim Listing Journal: Ann Rheum Dis Date: 2017-08-19 Impact factor: 19.103
Authors: A Prior-Español; C Sánchez-Piedra; J Campos; F J Manero; C Pérez-García; C Bohórquez; N Busquets-Pérez; J M Blanco-Madrigal; C Díaz-Torne; F Sánchez-Alonso; L Mateo; S Holgado-Pérez Journal: Sci Rep Date: 2021-05-27 Impact factor: 4.379
Authors: Silvia Sánchez-Ramón; Lidia Fernández-Paredes; Paula Saz-Leal; Carmen M Diez-Rivero; Juliana Ochoa-Grullón; Concepción Morado; Pilar Macarrón; Cristina Martínez; Virginia Villaverde; Antonia Rodríguez de la Peña; Laura Conejero; Keyla Hernández-Llano; Gustavo Cordero; Miguel Fernández-Arquero; Benjamin Fernández- Gutierrez; Gloria Candelas Journal: Front Immunol Date: 2021-06-04 Impact factor: 7.561
Authors: I Danés; A Agustí; A Vallano; C Alerany; J Martínez; J A Bosch; A Ferrer; L Gratacós; A Pérez; M Olmo; S M Cano Marron; A Valderrama; X Bonafont Journal: Eur J Clin Pharmacol Date: 2014-09-09 Impact factor: 2.953